Gamma-delta T cell receptor V-gamma-4 (Vγ4 TCR)

The Gamma-delta T cell receptor V-gamma-4 (Vγ4 TCR) is a specialized antigen-recognition complex found on a distinct subset of gamma-delta T cells that operate at the interface of innate and adaptive immunity (UniProt P0CF51). Unlike conventional alpha-beta T cells, Vγ4+ T cells recognize non-peptide antigens and stress-induced ligands in an MHC-independent manner, allowing for rapid responses to cellular stress, viral infections, and malignant transformation (Frontiers in Immunology, 2020). In humans, the Vγ4 chain, encoded by the TRGV4 gene, is involved in the immune surveillance of pathogens such as Cytomegalovirus and has demonstrated significant anti-tumor activity in various cancers, including hepatocellular and lung carcinoma. In murine models, Vγ4+ T cells are identified as a primary source of interleukin-17 (IL-17), playing a critical role in the pathogenesis of inflammatory conditions like psoriasis and rheumatoid arthritis (Nature Communications, 2017; Journal of Experimental Medicine, 2010). Therapeutic development targeting the Vγ4 TCR focuses on bispecific antibodies designed to redirect T-cell cytotoxicity toward tumors or antagonistic agents aimed at mitigating chronic autoimmune inflammation. However, the clinical application of these therapies requires careful management of potential safety concerns, such as cytokine release syndrome and the risk of exacerbating systemic inflammatory responses.

Other names

Vgamma4 TCRVγ4+ TCRT cell receptor gamma variable 4TRGV4TCR Vγ4

Agonistic activation of Vγ4+ T cells to promote anti-tumor cytotoxicity or antagonistic inhibition to suppress IL-17-mediated inflammation.